Ki-67/CD3 ratio in the diagnosis of chronic inflammatory enteropathy in dogs

Sonja Karlovits1, Anita Manz1, Karin Allenspach2, Ingrid Walter3,5, Stefan Kummer3, Alexander Tichy4, Barbara Richter5, Iwan A. Burgener1, Nicole Luckschander-Zeller1

1Department for Companion Animals and Horses, Clinic for Small Animal Internal Medicine, University of Veterinary Medicine, Vienna, Austria
2Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa
3VetCore Facility for Research, University of Veterinary Medicine, Vienna, Austria
4Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria
5Department for Pathobiology, Institute of Pathology, University of Veterinary Medicine, Vienna, Austria

Correspondence
Sonja Karlovits, Department for Companion Animals and Horses, Clinic for Internal Medicine, University of Veterinary Medicine, Vienna, Austria.
Email: sonja.karlovits@chello.at

Abstract
Background: T cells play a key role in the pathogenesis of chronic inflammatory enteropathy (CIE) in dogs. Cluster of differentiation 3 (CD3) antigen serves as a marker for T cells. In human medicine, Ki-67 is an indicator for cell growth but there are only a few studies in dogs with CIE.

Objective: To investigate Ki-67 in relation to T cells as a marker for CIE in dogs.

Animals: Eleven dogs with CIE and 6 healthy beagle controls (CO).

Methods: Retrospective case-control study. Dogs were clinically assessed by the Canine Chronic Enteropathy Clinical Activity Index (CCECAI). Duodenal mucosal biopsy samples were endoscopically obtained for histopathologic examination by means of the World Small Animal Veterinary Association score. Double-labeled immunofluorescence was used to investigate colocalization of Ki-67 and CD3 in epithelium and lamina propria (LP) of villi and crypts.

Results: Dogs with CIE had significantly higher clinical score (median, 5.0; interquartile range [IQR], 3-7) compared to CO (all 0; \( P < .001 \)). The Ki-67/CD3 double-positive cells were significantly increased in the LP of the crypt region of CIE dogs (0.63 cells/mm²; IQR, 0.00-0.54) versus CO (0.08 cells/mm²; IQR, 0.00-0.26; \( P = .044 \)). A significant correlation was found between CCECAI and the Ki-67/CD3 ratio in the LP of the crypt region (\( r = 0.670; P = .012 \)) in dogs with CIE.

Conclusions and Clinical Importance: The Ki-67/CD3 ratio is upregulated in the LP crypt region of dogs with CIE and it correlates with clinical severity. Therefore, Ki-67/CD3 could be a useful tool for detection of CIE.

Keywords: canine, diagnostic marker, inflammatory bowel disease, intestinal inflammation, T cells

INTRODUCTION

Chronic inflammatory enteropathy (CIE) in dogs is a collective term to describe disorders of the gastrointestinal (GI) tract characterized by...
persistent or recurrent GI signs such as vomiting, diarrhea, hyporexia, abdominal pain, nausea, and weight loss with histopathologic signs of intestinal inflammation.1

The etiology of CIE is not well understood. The current hypothesis is that intestinal inflammation develops in genetically predisposed dogs, through interactions among food components, environmental factors, and intestinal microbiota.2,3 In dogs, CIE is diagnosed based on exclusion of extra-GI as well as GI disorders of other etiology (eg, mechanical obstruction caused by foreign bodies, intestinal tumors, intussusception).4 In dogs, the type of CIE often is determined retrospectively by response to treatment and includes food-responsive diarrhea (FRD), antibiotic-responsive diarrhea (ARD), and idiopathic inflammatory bowel disease (IBD), which in most cases is steroid-responsive diarrhea (SRD).1,5,6

The cause of idiopathic CIE is unknown, but mounting evidence suggests that hypersensitivity and proliferation of T cells play key roles in the pathogenesis.7 The cluster of differentiation 3 (CD3) cell infiltrates in the duodenum of dogs with CIE decrease after treatment with cyclosporine, which decreases the expression of interleukin-2 (IL-2) that is necessary for T-cell survival.8 A multimeric protein complex, CD3 functions as a T-cell coreceptor.9 The T-cell response is initiated by presenting foreign antigen through the major histocompatibility complex molecule binding to the T-cell receptor-CD3 complex.10 The CD3 antigen is well known as a T-cell marker in both human as well as veterinary medicine.7,11

The Ki-67 antigen is expressed in all active phases of the cell cycle (G1, S, and G2) but it is absent in resting cells (G0 phase).12 Therefore, Ki-67 and CD3 thus can be considered proliferating T cells. Proliferating T cells have increased cytokine production, which may contribute to the clinical signs seen in patients with CIE.13-16

Our aim was to establish Ki-67/CD3 immunohistochemical double labeling in sections of canine duodenum. The first hypothesis was that a significant difference in Ki-67/CD3 expression would exist between dogs with CIE and healthy control dogs without GI signs (controls [CO]). The second hypothesis was that significant differences would be found in the number of Ki67/CD3 double-positive cells in different areas of the intestinal mucosa (lamina propria [LP] and lamina epithelialis of villi and crypts), thereby indicating areas of proliferation of mucosal T cells.

2 | MATERIALS AND METHODS

Protocols for this study were approved by the Institutional Ethics Committee, the Advisory Committee for Animal Experiments (§12 of Law for Animal Experiments, Tierversuchsgesetz), and the Federal Ministry for Science and Research (reference number: §8 GZ 68.205/0201-I/3b/2010).

2.1 | Study groups

2.1.1 | Control dogs

Six neutered male, clinic-owned beagle dogs 3 to 6 years of age without GI signs were classified as healthy based on history, clinical examination, CBC, biochemistry profile, fecal flotation, and Giardia antigen testing, and served as CO.

2.2 | Tissue preparation and staining

All biopsy samples were fixed in 4% neutral buffered formaldehyde and embedded in paraffin. Serial sections from paraffin tissue blocks were cut for standard Hematoxylin & Eosin staining as well as for IF microscopy. All slides were deparaffinized with xylene and rehydrated through a graded series of alcohols (100, 96, 70%) followed by distilled water at room temperature. Heat-induced epitope retrieval was performed in TRIS-EDTA buffer at pH 9 (Target Retrieval Solution, Ref S2367, Dako, Glostrup, Denmark) with a steamer for 30 minutes. After a cooling phase, the slides were washed 3 times in phosphate-buffered saline (PBS) with 0.025% Tween 20 for 5 minutes each. Protein blocking was performed with 1.5% goat serum (Dako, Glostrup, Denmark) in PBS.

2.1.2 | Dogs with chronic inflammatory enteropathy

This retrospective study was performed on dogs seen between 2011 and 2014. Diagnostic evaluation, endoscopic biopsy, and grading were part of a prospective study performed at this time and yielding biopsy samples that were retrospectively used in the present study for special staining and immunofluorescence (IF) microscopy.

Medical records of client-owned dogs in which CIE had been diagnosed at the Clinic for Internal Medicine at the Veterinary University of Vienna were reviewed retrospectively. Criteria for inclusion in the study were clinical signs consistent with CIE (eg, weight loss, vomiting, diarrhea) for longer than 4 weeks. No pretreatment was given 2 weeks before gastroduodenoscopy was performed in dogs included in the study. All CIE patients had histopathological evidence of small intestinal inflammation on endoscopically retrieved biopsy samples. Dogs with metabolic, parasitic, or neoplastic causes of GI signs as well as patients that were not clinically stable for gastroduodenoscopy were excluded from the study.

Eleven dogs met the inclusion criteria. All of the enrolled patients received a routine diagnostic evaluation including history, physical examination, CBC, biochemistry profile, basal cortisol concentration, serum cobalamin concentration, fecal flotation, Giardia antigen test as well as abdominal ultrasound examination to exclude infectious, endocrine, or neoplastic diseases as a cause for the GI signs. Gastroduodenoscopy was performed under general anesthesia, and 8 to 10 endoscopic biopsy samples were taken from the duodenum using a flexible endoscope. Control dogs underwent the same endoscopic procedure. All dogs (CIE and CO) were graded according to the Canine Chronic Enteropathy Clinical Activity Index (CCECAI).5 Biopsy samples were scored by means of the World Small Animal Veterinary Association (WSAVA) guidelines.17
Immunolabeling was performed by a primary antibody mix composed of a polyclonal rabbit anti-CD3 (DAKO, Glostrup, Denmark) at a dilution of 1:500 in PBS and monoclonal mouse anti-Ki67 (clone MM1, Novocastra/Leica, Wetzlar, Germany) at a dilution of 1:100 in PBS overnight at 4°C followed by 60 minutes at room temperature. The use of both antibodies previously has been validated for dogs.10,18,19

After a triple-washing step (5 minutes each) in PBS with 0.025% Tween 20, a secondary antibody mixture composed of goat anti-rabbit labeled with Alexa Fluor 488 and goat anti-mouse labeled with Alexa 568 (Life technologies/Thermo Fisher Scientific, Waltham, MA), both diluted 1:150 in PBS, was added and cells were incubated for 60 minutes on the shaker at room temperature. Nuclei were counterstained with Dapi (Sigma-Aldrich, MO) for 10 minutes and covered with Aqua-Poly/Mount (Polysciences Europe GmbH, 69493 Hirschberg an der Bergstrasse, Germany) and a coverslip.

As positive control samples, canine lymph node was used for CD3-staining and canine intestinal mucosa was used for Ki-67-staining. “No primary antibody” controls were used to show that there was no host specific binding of the secondary antibodies.

2.3 | Canine Chronic Enteropathy Clinical Activity Index and histopathology

All dogs were scored by CCECAI, which is a clinical scoring system including attitude, appetite, vomiting, fecal consistency, frequency of defecation, weight loss, serum albumin concentration, ascites, and peripheral edema as well as pruritus.5 Tissue samples were graded by a single blinded board-certified pathologist (BR) according to WSAVA guidelines.17

Four inflammatory histologic variables (intraepithelial lymphocytes, LP lymphocytes and plasma cells, LP eosinophils, and LP neutrophils) were scored in at least 8 specimens per dog and graded as normal = 0, mildly increased = 1, moderately increased = 2, and markedly increased = 3. The arithmetic mean for each variable then was determined for each patient.

2.4 | Fluorescence microscopy

The Ki-67/CD3 ratio was determined by counting double-positive cells in different layers of the intestinal wall (epithelium and LP of villi and crypts) in 15 representative fields of each slide by a single independent observer (S. Karlovits) with Zeiss Imager Z2 (Carl Zeiss Microscopy GmbH, Jena, Germany; Figure 1). Randomly selected slides were double-checked by another investigator (A. Manz) to verify results. Observers were blinded to patient and study group history. Double-positive cell counts were expressed as cells/mm².

The areas on the slides without tissue were extracted by 2 different computer programs—ilastik, an interactive learning and segmentation toolkit, as well as Fiji.20,21

Not all areas were available on each slide of every patient.

2.5 | Statistical analysis

Data were analyzed by IBM SPSS v24 (IBM Corporation, Armonk, NY). The assumption of normal distribution was tested using the Kolmogorov-Smirnov test. Because data were not normally distributed and because of small sample size, differences in variables such as CCECAI, WSAVA scoring and double-positive cells in the LP, and epithelium of villi and crypts between CIE and CO were analyzed using the nonparametric Mann-Whitney test. Holms correction method was used to adjust P-values for multiple testing. Results are given as median (MD) and interquartile range (IQR). Correlation between variables (CCECAI and Ki-67/CD3 ratio; WSAVA and Ki-67/CD3 ratio) was calculated by Spearman’s correlation coefficient. For all statistical tests, a P-value <.05 was considered significant.
RESULTS

3.1 Descriptive statistics

The CO (n = 6) consisted of healthy male neutered beagle dogs which were all 3 years of age. Median body weight was 17.0 kg (IQR, 16.9-17.2).

The CIE group (n = 11) consisted of each of the following: American Staffordshire Terrier, Boxer, Cavalier King Charles Spaniel, French Bulldog, German Shepherd, Groenendael, Jack Russell Terrier, Malinois, mixed breed dog, Pit Bull Terrier, and Shar Pei. Only the Shar Pei was clinically classified as having protein-losing enteropathy (PLE) because of panhypoproteinemia with hypoalbuminemia (serum albumin concentration, 15 g/L; reference range, 26-47 g/L). The MD age was 4 years (IQR: 3-5.3) and MD body weight was 17.5 kg (IQR, 10.6-27.4).

3.2 Canine Chronic Enteropathy Clinical Activity Index and histopathology

The CCECAI was significantly higher in CIE (5.0, IQR: 3-7) versus CO (all 0; P < .001; Figure 2).

Both CIE and CO had a MD WSAVA score of 1 (CIE, 1.0, IQR: 1.0-2.0; CO, 1.0; IQR, 1.0-1.3). The WSAVA score was not different between groups (P = .313; Figure 3).

3.3 Immunofluorescence

The LP of the crypt area had significantly higher expression of Ki-67/CD3 double-positive cells/mm² (MD, 0.63; IQR, 0-0.54; P = .044) compared to crypt epithelium, villus epithelium and villus LP (Figure 4A–D). In LP of the crypt area, a significant correlation was found between CCECAI and the Ki-67/CD3 ratio (r = 0.670; P = .012).

DISCUSSION

Currently, the diagnosis of CIE is based upon persistent or recurrent GI signs in combination with histopathologic signs of intestinal inflammation. However, the definitive diagnosis is difficult because often only a
few, very small endoscopic biopsy samples are available that may or may not be representative of the entire GI tract. Their quality depends on the experience of the operator obtaining the biopsy samples as well as interobserver variations in histopathological evaluation, despite a standardized grading system. Given the current limitations of the WSAVA scoring system, the demand for supportive diagnostic tools in CIE is increasing. Because hypersensitivity and proliferation of T cells may play a major role in the pathogenesis of CIE, the combination of Ki-67 as a proliferation marker and CD3 as a marker for T cells was used to investigate active T cells in different areas of the intestinal wall. Results of this study show a significant upregulation of Ki-67/CD3 double-positive cells in the crypt area of the LP in dogs with CIE (P = .044) compared to CO, indicating that it is a metabolically active region for T cells. However, crypt and villus epithelium as well as villus LP did not show a significant upregulation of double-positive cells. This study represents the first time that proliferation of T cells in the LP of CIE dogs has been evaluated and indicates that this proliferative ratio could be a more useful marker of clinical severity than the currently used WSAVA score and endoscopic grading.

The WSAVA score was not significantly different between the 2 study populations. This finding may be a consequence of the small size of the study population. Although a standardized grading system was used, histopathological interpretation is still subjective and influenced by staining techniques and interobserver variability. Previous studies found no change in the total number of T cells as well as severity of inflammatory infiltrates after treatment, and histological score was not associated with outcome in dogs with CIE. Despite the fact that the WSAVA scores comparing CO and CIE were not significantly different, the MD in the CIE group was higher than in the CO. Nevertheless, the CO consisted of beagles, which are not an ideal CO, and most of the CIE dogs were scored mildly. Although the Ki-67/CD3 ratio did not correlate with histopathological scoring, we detected a correlation with CCECAI. Proliferating T cells exhibit increased cytokine production, which may contribute to the clinical signs seen in patients with CIE.

The CD3 cell infiltrates in the duodenum of dogs with CIE decrease after treatment with cyclosporine, thus decreasing expression of IL-2, crucial for T-cell survival. Therefore, the routine use of immunohistochemical markers such as the Ki-67/CD3 ratio could aid in the interpretation of the histological score together with clinical scoring, because a significant difference was found between the groups in the crypt area in our study.

We found significant upregulation of Ki-67/CD3-positive cells in the LP of the crypt. This finding is in contrast to the normal distribution of T-cells in healthy dogs with an increasing cell density from crypt to villus tip, reflecting exposure to luminal antigens. This finding may be a result of higher epithelial destruction because of inflammation in the examined intestinal biopsy samples. Another explanation for this distribution could be that stem cells of the crypt LP show an increased proliferation rate during inflammation and higher amounts of destruction at the villus tip.

Our study had several limitations, mostly because of its retrospective character of our study, no ileal biopsy samples were available from both the CIE group and CO. Therefore, no results are available for the ileum, thus the multifocal character of the lesions in CIE with different degrees of severity in each region may have been missed. However, intraepithelial lymphocytes, lymphoplasmacytic infiltrates, and inflammatory changes tend to be more common in the duodenum than in the ileum, and significant differences in the Ki-67/CD3 ratio were identified in our study.

The CIE group included 1 dog with PLE. This fact must be interpreted with caution because PLE is not a single disease but a syndrome that develops in different diseases of different etiologies such as lymphatic obstruction, increased vascular permeability because of cytokines, or mucosal inflammation as in IBD (primarily caused by severe lymphoplasmatic enteritis). Another limitation was that not all areas were always available for every patient because of the nature of biopsy samples and cutting techniques.

The patients with CIE received different treatments before endoscopic diagnosis was made, ranging from diet alone, a combination of different diets, antibiotics, prednisolone, and deworming. However, all treatments were discontinued at least 2 weeks before endoscopy. Therefore, pretreatment should not be a confounding factor.

For future prospective studies, it would be preferable to have a CO consisting of dogs of different breeds, sex, and age, avoiding the selection bias of our study. Although no significant difference in age was found between the 2 study populations in our study, dogs with FRD generally are younger than those with SRD. Furthermore, grouping of patients according to their response to treatment for FRD, ARD, and SRD, as well as outcome, would be preferable. Re-evaluation of the status of the disease using endoscopically biopsy samples to determine if the Ki-67/CD3 ratio decreases with improvement in clinical signs also would be needed in future studies to ascertain its value as a prognostic and therapeutic marker.

In conclusion, we report significant upregulation of Ki-67/CD3 double-positive cells in the LP in the crypt area of dogs with CIE as compared to CO as well as a correlation of Ki-67/CD3 with clinical severity as determined by CCECAI score. Given the current limitations of the WSAVA scoring system, the Ki-67/CD3 ratio could be a promising tool to aid in the diagnosis of CIE, but more studies with a larger study population of dogs are needed.

ACKNOWLEDGMENTS
The authors acknowledge M. Labato for the support with the manuscript and U. Reichart for the advice with the computer programs (ilastik and Fiji). This research was supported by resources of the VetCore Facility (VetBioBank, VetImaging) of the University of Veterinary Medicine Vienna. This study was presented as an abstract at the 2017 ACVIM Forum, National Harbor, MD.

CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.

OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION
Authors declare no IACUC or other approval was needed.

HUMAN ETHICS APPROVAL DECLARATION
Authors declare human ethics approval was not needed for this study.

ORCID
Sonja Karlovits https://orcid.org/0000-0002-8420-2042
Iwan A. Burgener https://orcid.org/0000-0002-8516-0040

REFERENCES
1. Giaretta PR, Rech RR, Guard BC, et al. Comparison of intestinal expression of the apical sodium-dependent bile acid transporter between dogs with and without chronic inflammatory enteropathy. J Vet Intern Med. 2018;32(6):1918-1926.
2. German AJ, Hall EJ, Day M. Chronic intestinal inflammation and intestinal disease in dogs. J Vet Intern Med. 2003;17(1):8-20.
3. Allenspach K, House A, Smith K, et al. Evaluation of mucosal bacteria and histopathology, clinical disease activity and expression of toll-like receptors in German Shepherd Dogs with chronic enteropathies. Vet Microbiol. 2010;146(3-4):326-335.
4. Bliourge V, Ankringa N, German AJ. A randomized, open-label, positively-controlled field trial of a hydrolyzed protein diet in dogs with chronic small bowel enteropathy. J Vet Intern Med. 2010;24(6):1350-1357.
5. Allenspach K, Wieland B, Gröne A, Gaschen F. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J Vet Intern Med. 2007;21:700-708.
6. Wennogle SA, Priestnall SL, Webb CB. Histopathologic characteristics of intestinal biopsy samples from dogs with chronic inflammatory enteropathy with and without hypoaalbuminemia. J Vet Intern Med. 2017;3(1):371-376.
7. Sauter SN, Allenspach K. Clinical signs, histology, and CD3-positive cells before and after treatment of dogs with chronic enteropathies. J Small Anim Pract. 2008;23(5):1079-1083.
8. Allenspach K, Rüfenacht S, Sauter S, et al. Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease. J Vet Intern Med. 2006;20:239-244.
9. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. J Comp Pathol. 1999;120(3):221-239.
10. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. J Comp Pathol. 2000;123(3):221-239.
11. Kiupel M, Teske E, Bostock D. Prognostic factors for treated canine malignant lymphoma. Vet Pathol. 1999;36(4):292-300.
12. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol Cell Physiol. 2000;182(3):311-322.
13. German AJ, Helps CR, Hall EJ, et al. Cytokine mRNA expression in mucosal biopsies from German Shepherd Dogs with small intestinal enteropathies. Dig Dis Sci. 2000;45(1):7-17.
14. Guy-Grand D, DiSanto JP, Henchoz P, et al. Small bowel enteropathy: role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-γ, TNF) in the induction of epithelial cell death and renewal. Eur J Immunol. 1998;28(2):730-744.
15. McKay DM, Baird AW. Cytokine regulation of epithelial permeability and ion transport. Gut. 1999;44(4):283-289.
16. Ridyard AE, Nutall TJ, Else RW, Simpson JW, Miller HRP. Evaluation of Th1, Th2 and immunosuppressive cytokine mRNA expression within the colonic mucosa of dogs with idiopathic lymphocytic-plasmacytic colitis. Vet Immunol Immunopathol. 2002;86(3-4):205-214.
17. Day MJ, Blizer T, Mansell J, et al. Histopathological standards for the diagnosis of gastrointestinal inflammation in endoscopic biopsy samples from the dog and cat: a report from the World Small Animal Veterinary Association gastrointestinal standardization group. J Comparative Pathol. 2008;138:1-43.
18. Bollig N, Kong G, Pan X, et al. JAK 1/2 inhibitors AZD1480 and CYT387 inhibit canine B-cell lymphoma growth by increasing apoptosis and disrupting cell proliferation. J Vet Intern Med. 2017;31:1804-1815.
19. Golaz JL, Vonlaufen N, Hemphill A, Burgener IA. Establishment and characterization of a primary canine duodenal epithelial cell culture. Vet Cell Dev Biol Anim. 2007;43(5-6):176-185.
20. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji—an open source platform for biological image analysis. Nat Methods. 2012;9(7):676-682.
21. Sommer C, Straehle C, Ulrich K, et al. Ilastik: interactive learning and segmentation toolkit. Eighth IEEE Int Symp Biomed Imaging. 2011;230-233.
22. Kathrani A, House A, Catchpole B, Murphy A, Werling D, Allenspach K. Breed-independent toll-like receptor 5 polymorphisms show association with canine inflammatory bowel disease. Tissue Antigens. 2011;78(2):94-101.
23. Slovak JE, Wang C, Morrison JA, et al. Endoscopic assessment of the duodenum in dogs with inflammatory bowel disease. J Vet Intern Med. 2014;28(5):1442-1446.
24. Jergens AE, Willard MD, Allenspach K. Maximizing the diagnostic utility of endoscopic biopsy in dogs and cats with gastrointestinal disease. Vet J. 2016;214:50-60.
25. Luckshander N, Reichart U, Richter B, et al. The role of signal transducer and activation of transcription (STAT) 3 in dogs with chronic enteropathies. J Vet Intern Med. 2014;28(2):711-744.
26. Dandrieux JR, Doherr MG, Kano R, et al. Evaluation of lymphocyte apoptosis in dogs with inflammatory bowel disease. Am J Vet Res. 2008;69(10):1279-1285.
27. Elwood CM, Hamblin AS, Batt RM. Quantitative and qualitative immunohistochemistry of T cell subsets and MHC class II expression in the canine small intestine. Vet Immunol Immunopathol. 1997;58(3-4):195-207.
28. German AJ, Hall EJ, Day M. Analysis of leucocyte subsets in the canine intestine. J Comp Pathol. 1999;120(2):129-145.
29. Andrews C, McLean MH, Durum SK. Cytokine tuning of intestinal epithelial function. Front Immunol. 2018;9:1270.
30. Procoli F, Motsküla PF, Keyte SV, et al. Comparison of histopathologic findings in duodenal and ileal endoscopic biopsies in dogs with chronic small intestine enteropathies. J Vet Intern Med. 2013;27(2):268-274.
31. Casamian-Sorrosal D, Willard MD, Murray JK, Hall EJ, Taylor SS, Day MJ. Comparison of histopathologic findings in biopsies from the duodenum and ileum of dogs with enteropathy. J Vet Intern Med. 2010;24(1):80-83.
32. Craven MD, Washabau RJ. Comparative pathophysiology and management of protein-losing enteropathy. J Vet Intern Med. 2019;33(2):383-402.
33. Equilinio M, Théodoloz V, Gorgas D, et al. Marker concentrations and survival time in dogs with protein-losing enteropathy. JAVMA. 2015;246(1):91-99.

How to cite this article: Karlovits S, Manz A, Allenspach K, et al. Ki-67/CD3 ratio in the diagnosis of chronic inflammatory enteropathy in dogs. J Vet Intern Med. 2020;34:92-97. https://doi.org/10.1111/jvim.15680